We are live on ! Find out more

Incyte

INCY

Market cap $23.7B

116.80 USD

-0.07

0.06%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

118.49

+1.69

1.45%

1 day

-0.06%

5 days

0.04%

1 month

-5.19%

3 months

-8.1%

6 months

17.86%

Year to date

15.16%

1 year

29.52%

5 years

74.38%

10 years

34.3%

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Employees: 2,844

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 38.1%

Neutral 59.5%

Negative 2.4%

Zacks Investment Research

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

What Incyte (INCY) Said on Its Q3 Earnings Call

Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.

What Incyte (INCY) Said on Its Q3 Earnings Call

Zacks Investment Research

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.

Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”

Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Zacks Investment Research

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

See News Rankings

Price charts implemented using Lightweight Charts™